About Schwannomin-interacting protein 1
Schwannomin-interacting protein 1 (SCHIP1) is a protein
from Homo sapiens identified by UniProt accession
P0DPB3, 487 residues long.
MolForge cross-references it against 0 known binders and
51 disease associations.
Target properties
| Protein name | Schwannomin-interacting protein 1 |
| UniProt accession | P0DPB3 |
| Gene | SCHIP1 |
| Organism | Homo sapiens |
| Length | 487 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (51)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- celiac disease · score 0.33
- lymphocyte count · score 0.32
- familial meningioma · score 0.27
- platelet crit · score 0.24
- Behcet's syndrome · score 0.24
- von Willebrand factor measurement · score 0.22
- eosinophil count · score 0.22
- Oral ulcer · score 0.21
- ulcer disease · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0DPB3-F1 | alphafold | PREDICTED | 60.32 | — |
Amino-acid sequence (487 residues)
MERSGQRVTT WDCDQGKHSD SDYREDGMDL GSDAGSSSSS SRASSQSNST KVTPCSECKS SSSPGGSLDL VSALEDYEEP FPVYQKKVID EWAPEEDGEE EEEEDERDQR GYRDDRSPAR EPGDVSARTR SGGGGGRSAT TAMPPPVPNG NLHQHDPQDL RHNGNVVVAG RPSCSRGPRR AIQKPQPAGG RRSGRGPAAG GLCLQPPDGG TCVPEEPPVP PMDWEALEKH LAGLQFREQE VRNQGQARTN STSAQKNERE SIRQKLALGS FFDDGPGIYT SCSKSGKPSL SSRLQSGMNL QICFVNDSGS DKDSDADDSK TETSLDTPLS PMSKQSSSYS DRDTTEEESE SLDDMDFLTR QKKLQAEAKM ALAMAKPMAK MQVEVEKQNR KKSPVADLLP HMPHISECLM KRSLKPTDLR DMTIGQLQVI VNDLHSQIES LNEELVQLLL IRDELHTEQD AMLVDIEDLT RHAESQQKHM AEKMPAK
Explore Schwannomin-interacting protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets